Oxford Biomedica strikes €15M deal to acquire French CDMO ABL Europe
05 Dec 2023
AcquisitionGene Therapy
Preview
Source: FiercePharma
Oxford Biomedica plans to buy French CDMO ABL Europe for 15 million euros ($16 million), getting two production sites in the process.
Oxford Biomedica agreed to acquire French CDMO ABL Europe, a subsidiary of Institut Mérieux, for 15 million euros ($16 million) in a deal that will give the drugmaker expanded viral vector capabilities.
The purchase is expected to be completed in the first quarter of 2024, the company said in a Dec. 4 release. Back in September, Oxford Biomedica said it had entered "exclusive negotiations" to purchase ABL.
“We will now be establishing a significant presence in the EU, while also freeing up Oxford Biomedica’s capacity to better serve our growing client demand worldwide,” Dr. Frank Mathias, Oxford Biomedica’s chief executive, said in the Monday release.
With the deal, Oxford Biomedica picks up production facilities in Lyon and Strasbourg, France. The buyout increases the company's capacity in process and analytical development and early-stage manufacturing. ABL Europe works on more than 10 cell and gene therapy programs spanning disease areas that include more than six different vector types.
Going forward, Oxford Biomedica will be able to offer multi-viral vector CDMO capabilities, boasting six manufacturing sites in EU, U.S. and U.K., the company said.
The push to buy ABL began at the same time Oxford increased its break-even forecast from the first half of 2025 to the second half of 2024 due to expected revenue growth from new and existing clients.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.